Community Oncology Alliance offers a network for practice leaders and administrators to collaborate on community oncology challenges.
Public source
Publisher name
Public post
Smooth practice operations require structured, team-wide problem solving. At the 2026 Community Oncology Conference, practice leaders mapped out how they successfully tu…
Company
Community Oncology Alliance
Strengthening independent community oncology practices.
- Industry
- Public Policy Offices
- Location
- Washington, US
- Company size
- 11–50 employees
About Community Oncology Alliance
The Community Oncology Alliance (COA) is a non-profit organization dedicated solely to improving access to community cancer care, where the majority of Americans with cancer are treated. COA leads community cancer clinics in navigating an increasingly challenging environment to provide efficiencies, patient advocacy, and proactive solutions to Congress and policymakers.
See moreLatest activity
Latest activity from Community Oncology Alliance
4 signals
Research & Knowledge
Community Oncology Alliance examined the state of CAR T-cell therapy access in community oncology, including geographic and logistical barriers, reimbursement issues, and quality and safety standards.
Presence & Recognition
Community Oncology Alliance is hosting the virtual Lymphoma Day of Education on Thursday, September 17 at 10am ET for oncology pharmacists to earn 4.75 continuing education credits.
Presence & Recognition
Community Oncology Alliance hosted the 2026 Community Oncology Conference where practice leaders mapped out how they turn clinical issues into quality improvement projects.
Discover more
Similar signals
Similar public activity from other companies.
Products & Services
CancerNavigator
CancerNavigator navigators connect with newly diagnosed patients to decode complex NCCN treatment options into plain language and guide them to a high-quality, cost-effective community oncology center.
Research & Knowledge
Friends of Cancer Research
Friends of Cancer Research published a recent manuscript highlighting findings from a study showing that China's National Medical Products Administration (NMPA) approved more novel oncology drugs than the FDA between 2020 and 2025.
Products & Services
CancerIQ
CancerIQ helps health systems identify patients with possible hereditary or familial risk within existing workflows to provide education and resources for counseling, testing, screening, and ongoing care.
Products & Services
Community Health Media
Community Health Media is extending treatment options for patients across the HER2 landscape, including HER2-positive, HER2-low, and HER2-ultralow patients.
Products & Services
OncoAlert